Identification of Pro-Differentiation Patterns by Gene Expression Analysis following Pioglitazone Treatment in a Primary Laryngeal Tumor Cell Line
✍ Scribed by Nathan R. Handley; Patrick M. Gaffney; Randall S. Taylor; Beverly R. Wuertz; Frank G. Ondrey
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 485 KB
- Volume
- 121
- Category
- Article
- ISSN
- 0023-852X
No coin nor oath required. For personal study only.
✦ Synopsis
Head and neck squamous cell carcinoma (HNSCC) affects nearly 500,000 individuals worldwide each year, with nearly 40,000 patients in the US alone.
The 5-year survival rate is approximately 50%, and has not improved significantly in the past 20 years despite extensive efforts to increase cure rates. As such, there exists a need for safe therapeutics to improve survival. Recent efforts have turned toward chemopreventative measures to fulfill this need. The peroxisome proliferator-activated receptor (PPAR ), initially investigated for its role in adipocyte differentiation, has pro-apoptotic and antiangiogenic effects as well, leading to interest in the use of PPAR agonists for cancer treatment. A non-randomized phase II clinical trial at the U of MN demonstrated pioglitazone (Actos®), a PPAR agonist of the thiazolidinedione (TZD) drug class which is FDA approved for diabetes, clinically reduced preneoplastic leukoplakia lesions which often lead to HNSCC. An additional recent study from the U of MN utilized microarrays to analyze the extent to which differential gene modulation occurs in tumor vs. non-tumor human oral squamous cells and elucidate a gene expression profile reflective of tumorigenesis. However, no study has yet been performed which attempts to specifically analyze differential gene expression between normal, tumor, and pioglitazone-treated tumor cells on a genome-wide basis. This analysis serves as a pilot project to assess the feasibility of such a study.